KBC Group NV boosted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 53.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,151 shares of the company’s ...
In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Blueprint Medicines (BPMC – Research Report), with a ...
US biotech Kymera Therapeutics has begun a strategic collaboration with Sanofi to develop and market several drugs tackling immune-inflammatory disease, which could be worth up to $2 billion. The ...
Zacks.com on MSN3d
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Tops Revenue EstimatesBeyond Air, Inc. (XAIR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.50 per share a year ago. These figures are ...
A recent study published in Nature Communications by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) and collaborators evaluated a replicating RNA (repRNA) vaccine ...
After hours: February 7 at 6:37:11 PM EST Loading Chart for BCYC ...
After hours: February 7 at 4:02:41 PM EST Loading Chart for EWTX ...
After hours: February 5 at 5:11:57 p.m. EST ...
Pre-Market: 8:00:00 a.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback